Zydus Lifesciences Limited — Credit Ratings, 30-12-2024: Credit Rating

Consolidated revenue for Zydus Lifesciences Limited rose 13% year-over-year in fiscal 2024 and 20% in the first half of fiscal 2025, driven by strong sales growth in the US, new product launches, stable pricing, and robust performance in international markets. The domestic market also experienced steady growth due to increased volume and high-value therapies. Operating margins improved significantly to 27.5% for fiscal 2024, rising to 31% in the first half of fiscal 2025, reflecting better business mix and stable input costs despite ongoing R&D investments.

Net profit for the half-year ending September 30, 2024, reached Rs 2,402 crore, up from Rs 1,939 crore in the same period last year, indicating a robust Earnings Per Share (EPS) growth. In terms of operational efficiencies, gross debt reduced to Rs 150 crore, showcasing improved cash flows and a net cash position of Rs 2,591 crore.

Looking ahead, Zydus is positioned to sustain a revenue growth of 10-12% annually, bolstered by an impressive pipeline of new chemical entities and biosimilars, with operating margins expected to remain strong at 26-28%. The company's low debt levels and strong liquidity further underpin its financial health.

Investor Insight: Given the firm’s solid financial performance and growth outlook, a "buy" perspective seems warranted as Zydus continues to capitalize on its strong market position and expanding product portfolio.